New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2014
06:33 EDTFMI, CLVSFoundation Medicine and Clovis Oncology partner for cancer diagnostic
Foundation Medicine (FMI) and Clovis Oncology (CLVS) are expanding their ongoing collaboration to incorporate a coordinated regulatory strategy for the development of a novel Premarket Approval companion diagnostic test. This test is designed for use by physicians to identify patients most likely to respond to rucaparib, Clovis’ poly polymerase inhibitor currently the subject of Phase 2 and Phase 3 clinical trials in patients with ovarian cancer. This companion diagnostic is being developed in parallel with the clinical development of rucaparib to facilitate an FDA submission of the PMA for the companion diagnostic concurrent with the New Drug Application for rucaparib.
News For FMI;CLVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
07:16 EDTFMICowen to hold a conference
35th Annual Health Care Conference is being held in Boston on March 2-4 with webcasted company presentations to begin on March 3 at 8 am; not all company presentations may be webcasted. Webcast Link
March 2, 2015
07:20 EDTFMICowen to hold a conference
Subscribe for More Information
February 25, 2015
18:24 EDTCLVSOn The Fly: After Hours Movers
Subscribe for More Information
16:09 EDTCLVSClovis reports Q4 EPS ($1.62), consensus ($1.30)
Subscribe for More Information
10:01 EDTFMIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:23 EDTFMIFoundation Medicine downgraded at Wedbush
Subscribe for More Information
07:55 EDTFMIFoundation Medicine price target raised to $60-$65 from $55-$60 at Wells Fargo
Subscribe for More Information
07:18 EDTFMIG Corp to hold annual meeting
Subscribe for More Information
06:56 EDTFMIFoundation Medicine downgraded to Neutral from Outperform at Wedbush
February 24, 2015
16:03 EDTFMIFoundation Medicine sees FY15 revenue $105M-$115M, consensus $108.47M
The company expects to report between 43,000 and 47,000 clinical tests in 2015. The company expects operating expenses in the range of $128M-$138M. The company expects to launch a cell-free DNA test in 2015.
16:02 EDTFMIFoundation Medicine reports Q4 EPS (47c), consensus (51c)
Reports Q4 revenue $18.7M, consensus $18.05M.
February 23, 2015
06:31 EDTFMIFoundation Medicine and H3 Biomedicine announce collaboration
Foundation Medicine announced a multi-year collaboration for the discovery and development of precision medicines in oncology. The collaboration marries Foundation Medicine’s comprehensive genomic knowledgebase of more than 35,000 genomic profiles, FoundationCORE, with H3 Biomedicine’s drug discovery engine and computational biology platform. The approach aims to identify potential drug targets based on the unique genomic dependencies of individual cancers, rapidly accelerate clinical development, and lead to the commercialization of new, safe and effective precision medicines for individuals living with cancer. Under the terms of the agreement, H3 Biomedicine will pay Foundation Medicine a technology access fee for identification of target concepts arising from FoundationCORE and success milestones for selection, validation, clinical progression, and commercialization of products developed from the program. In addition, Foundation Medicine is eligible to receive royalties on sales of any products resulting from the collaboration.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use